Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 5/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.39 |
| ▸ | MTOR | P42345 | 2/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 2/20 | 0.38 |
| ▸ | FAAH | O00519 | 6/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | GALR3 | O60755 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3731840 | 0.94 | MAPK1 (0.40) | MAPK1RORCEPHX2NAMPT | |
| SCHEMBL3744307 | 0.94 | NAMPT (0.40) | MAPK1RORCPIK3CAMTORPIK3CD | |
| SCHEMBL3726790 | 0.88 | ALDH1A1 (0.41) | MAPK1RORCNAMPTRAB9ANPC1 | |
| SCHEMBL3742347 | 0.88 | FAAH (0.41) | MAPK1PIK3CAMTORPIK3CDPIK3CB | |
| SCHEMBL3746384 | 0.87 | PIK3CA (0.42) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL3731440 | 0.86 | NAMPT (0.43) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL3736336 | 0.82 | NAMPT (0.43) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL3733714 | 0.82 | NAMPT (0.44) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL3739030 | 0.82 | CYP3A4 (0.44) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL3744319 | 0.82 | ALDH1A1 (0.47) | NAMPTFAAHALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825120-B2 | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas | CYTOKINETICS, INC. (US) | 2010-11-02 | — | — | US | claimed |
| US-20070197504-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2007-08-23 | — | — | US | claimed |
| US-7825120-B2 | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas | CYTOKINETICS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| EP-1959963-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| US-20070197504-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2007089336-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197504-A1 | Certain chemical entities, compositions and methods | TNNI3, TNNT2, MYLK2 | MAPK1 3229/4885RORC 2972/4885PIK3CA 4067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.